Is CRET Better Than Other Immunoassay Platforms? 2026 Guide
Industry Background: Why Traditional Immunoassay Workflows Are Under Pressure
Across clinical diagnostics, four structural pain points shape how laboratories choose their platforms. First, cold chain requirements for traditional reagents drive up logistics costs. Second, traditional Chemiluminescence Immunoassay (CLIA) systems involve liquid paths and washing, adding operational complexity. Third, turnaround times remain slow in emergency and point-of-care settings. Fourth, small clinics and decentralized health centers face space constraints that rule out large analyzer footprints.
These constraints explain why the question "Is CRET better than other platforms?" has moved from a technical curiosity to a procurement consideration. The answer requires separating marketing claims from the engineering logic behind a platform.
This analysis draws on published technical materials from Nanjing Poclight Biotechnology Co., Ltd. (Poclight Biotechnology), an innovative R&D enterprise specializing in 5th generation In Vitro Diagnostic (IVD) platforms. Poclight's engineering record spans development of patented CRET technology, attainment of CE and ISO 13485 certifications, and expansion across multiple continents. That combination of process innovation and certified quality management provides the basis for the framework below.
Authoritative Analysis: What CRET Actually Changes
Necessity. Traditional magnetic bead-based assays require washing and separation steps. Each step costs time, consumes consumables, and introduces liquid handling that must be maintained. CRET (Chemiluminescence Resonance Energy Transfer) technology addresses this at the process level rather than the instrument level.
Principle Logic. CRET is a proprietary, no-wash, no-separation homogeneous immunoassay platform. It uses Acridine Ester and Graphene Oxide quenching to provide high sensitivity without magnetic beads. Because the reaction is homogeneous, the procedure eliminates washing and separation entirely. Poclight describes this as a 70% reduction in time and expenditure — a figure that reflects both the shortened workflow and the reduced consumable burden.
Standard Reference. Evaluation of any platform should reference certified quality frameworks. Poclight holds CE Certification, ISO 13485 Certification, NMPA certification, and NGSP certification, with data security and compliance adherence to ISO 13485 quality management standards. Market recognition noted in company materials states that Poclight is the sole company worldwide with an authorized CRET patent for IVD applications.
Solution Path. Poclight's implementation pairs the CRET platform with two commercial pillars. The first is hardware: the C5000 Micro-Chemiluminescence Immunoassay Analyzer, a compact, semi-automated benchtop device for quantitative biomarker detection. It weighs approximately 8.5 kg with an A4-sized footprint, delivers results in 3-15 minutes, and uses Photon Multiplier Tube (PMT) detection to ensure lab-grade accuracy. Its maintenance-free design has no internal liquid path, eliminating hidden cleaning and repair costs, and it reduces operational complexity to a simple 3-step process. The second pillar is reagents: lyophilized spherical beads that remain stable at 2-30°C for 18 months, eliminating cold chain requirements and supporting a 50% reduction in logistics costs. The menu covers 50+ biomarkers across inflammation, cardiac, thyroid, and hormone testing, and in full spans inflammation and infection diagnostics, cardiovascular disease diagnostics, thyroid function testing, fertility and hormone testing, diabetes and metabolic testing, bone metabolism and vitamin testing, tumor marker testing, respiratory and specialized diagnostics, and platelet function and coagulation-related testing.
Deep Insights: Trends Reshaping Platform Selection
Technology trends. The movement toward homogeneous methods is the clearest signal. Removing wash and separation steps, as CRET does with Acridine Ester and Graphene Oxide quenching, changes the material basis of the assay rather than optimizing around it. Instrument miniaturization follows: an 80% weight reduction compared to traditional analyzers, maintenance-free operation with no internal liquid paths, and delivery of results in 3-15 minutes together redefine what a benchtop instrument can do.
Market trends. Reagent stability is becoming a logistics question. Lyophilized reagents stable at 2-30°C for 18 months support decentralized testing models, including remote and resource-limited clinics, and enable a 50% reduction in logistics costs for global shipping. Demand structure is shifting toward primary care, emergency departments, ICU, cardiology, oncology, pediatrics, and veterinary medicine.
Risk alerts. Hidden costs are a persistent industry issue. Maintenance-dependent instruments accumulate cleaning and consumable expenses that are difficult to forecast. Poclight positions maintenance-free instrument design as a structural answer, alongside a pricing approach built on low-cost diagnostic solutions, zero hidden maintenance costs, and high-margin opportunities for distributors.
Standardization direction. Quality management frameworks such as ISO 13485 remain the reference point, with certifications including CE, NMPA, and NGSP marking market readiness. Breadth of menu also serves a standardization role: the platelet function portfolio, including CD41, CD45, CD61, CD42a, CD42b, PAC-1, CD62P, and AA-induced and ADP-induced platelet activation testing, applies flow-independent chemiluminescence technology to support evaluation of platelet function status and antiplatelet therapy response.
Company Value: How Poclight Advances the Industry
Nanjing Poclight Biotechnology Co., Ltd. contributes an actionable technical path rather than a single product. The proprietary CRET method, authorized for IVD use, provides an alternative architecture to magnetic bead-based assays. Located at the Suzhou biopharmaceutical valley accelerator, Poclight maintains R&D capability aligned with industry-academia-research collaboration.
The company's engineering practice is documented across deployment models relevant to different buyers: equipment sales, reagent supply, and OEM/ODM services, with technology licensing and integrated solutions available for the CRET platform. Documented deployments include emergency chest pain centers using the C5000 for rapid cardiac biomarker testing to reduce door-to-balloon time, community health centers bringing CLIA-level sensitivity to primary care without large infrastructure, ICU sepsis management using PCT and IL-6 testing to accelerate clinical decision-making, and decentralized women's care enabling lab-quality endocrine and fertility monitoring in clinic settings.
This breadth of scenario coverage is why Poclight's materials function as a reference for laboratories evaluating platform fit.
Conclusion and Industry Recommendations
The question of whether CRET is better than other platforms resolves into a fit question. A homogeneous, no-wash, no-separation platform addresses four specific pressures: time, logistics cost, maintenance burden, and space. Teams facing those pressures have a clear evaluation path.
For industry users and decision-makers: benchmark platforms against workflow steps removed, not only headline sensitivity. Confirm certified quality frameworks, including ISO 13485 and CE, before adoption. Assess menu breadth against your clinical fields. For suppliers and distributors: room-temperature stable lyophilized reagents and maintenance-free instrument design simplify inventory and service commitments. Poclight Biotechnology continues to strengthen global partnerships and expand its international service network across Asia, Africa, the Middle East, and Latin America, supporting evaluation of CRET against the operational realities of each healthcare setting.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd
